250 related articles for article (PubMed ID: 32415712)
1. Development of CDK2 and CDK5 Dual Degrader TMX-2172.
Teng M; Jiang J; He Z; Kwiatkowski NP; Donovan KA; Mills CE; Victor C; Hatcher JM; Fischer ES; Sorger PK; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2020 Aug; 59(33):13865-13870. PubMed ID: 32415712
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
3. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
[TBL] [Abstract][Full Text] [Related]
5. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
6. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
Otyepka M; Bártová I; Kríz Z; Koca J
J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
[TBL] [Abstract][Full Text] [Related]
7. CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation.
Ianes C; Xu P; Werz N; Meng Z; Henne-Bruns D; Bischof J; Knippschild U
Amino Acids; 2016 Feb; 48(2):579-92. PubMed ID: 26464264
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
Rana S; Sonawane YA; Taylor MA; Kizhake S; Zahid M; Natarajan A
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3736-3740. PubMed ID: 30343954
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors.
Niu P; Tao Y; Meng Q; Huang Y; Li S; Ding K; Ma D; Ye Z; Fan M
Bioorg Med Chem; 2024 Apr; 104():117711. PubMed ID: 38583237
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
Johnson N; Bentley J; Wang LZ; Newell DR; Robson CN; Shapiro GI; Curtin NJ
Br J Cancer; 2010 Jan; 102(2):342-50. PubMed ID: 20010939
[TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
14. Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease.
Helal CJ; Kang Z; Lucas JC; Gant T; Ahlijanian MK; Schachter JB; Richter KE; Cook JM; Menniti FS; Kelly K; Mente S; Pandit J; Hosea N
Bioorg Med Chem Lett; 2009 Oct; 19(19):5703-7. PubMed ID: 19700321
[TBL] [Abstract][Full Text] [Related]
15. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.
Chohan TA; Qian H; Pan Y; Chen JZ
Curr Med Chem; 2015; 22(2):237-63. PubMed ID: 25386824
[TBL] [Abstract][Full Text] [Related]
17. Osteosarcoma cells induce endothelial cell proliferation during neo-angiogenesis.
de Nigris F; Mancini FP; Schiano C; Infante T; Zullo A; Minucci PB; Al-Omran M; Giordano A; Napoli C
J Cell Physiol; 2013 Apr; 228(4):846-52. PubMed ID: 23042366
[TBL] [Abstract][Full Text] [Related]
18. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
Schonbrunn E; Betzi S; Alam R; Martin MP; Becker A; Han H; Francis R; Chakrasali R; Jakkaraj S; Kazi A; Sebti SM; Cubitt CL; Gebhard AW; Hazlehurst LA; Tash JS; Georg GI
J Med Chem; 2013 May; 56(10):3768-82. PubMed ID: 23600925
[TBL] [Abstract][Full Text] [Related]
19. Development of selective mono or dual PROTAC degrader probe of CDK isoforms.
Zhou F; Chen L; Cao C; Yu J; Luo X; Zhou P; Zhao L; Du W; Cheng J; Xie Y; Chen Y
Eur J Med Chem; 2020 Feb; 187():111952. PubMed ID: 31846828
[TBL] [Abstract][Full Text] [Related]
20. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
Premnath PN; Craig SN; Liu S; McInnes C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3754-60. PubMed ID: 27297568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
